Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Paion AG (PA8) NPV(BR)

Sell:€1.76 Buy:€1.77 Change: €0.006 (0.34%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.006 (0.34%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.006 (0.34%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Contact details

Heussstrasse 25
+49 (241) 44530

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€125.55 million
Shares in issue:
71.34 million
Frankfurt Stock Exchange

Key personnel

  • Joerg Spiekerkoetter
    Chairman of the Supervisory Board
  • James Phillips
    Chairman of the Management Board, Chief Executive Officer
  • Karin Dorrepaal
    Deputy Chairman of the Supervisory Board
  • Abdelghani Omari
    Chief Financial Officer, Member of the Management Board
  • Juergen Beck
    Member of the Management Board, Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.